Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 10, 2018

View Archived Issues

Patient enrollment ongoing in phase I trial of the GBM vaccine candidate VBI-1901

Novartis patents novel HBsAg secretion inhibitors

Baxter buys two hemostasis products from Mallinckrodt

The Medicines Co. closes sale of infectious disease business unit to Melinta Therapeutics

TG Therapeutics obtains rights to Jiangsu Hengrui's BTK inhibitor program

Machine learning framework allows 99% accurate ligand binding predictions

Lenvima plus Keytruda obtains FDA breakthrough therapy designation in RCC

Axsome Therapeutics announces results of IDMC interim analysis of COAST-1 and CREATE-1 trials

Novel polycomb protein EED inhibitors identified at Novartis

Roche discovers novel cannabinoid CB2 receptor ligands

Incysus submits second IND application to FDA

AVID-200 shows promise for the treatment of myelodysplastic syndrome-related anemia

Nerviano Medical Sciences patents new HsPEK inhibitors

Global Blood Therapeutics' voxelotor given breakthrough therapy designation for sickle cell disease

Molecular Partners reports initial data from phase II study of MP-0250 in multiple myeloma

Adapsyn enters into research collaboration with Pfizer

GenSight cleared by MHRA to begin phase I/II study of GS-030 gene therapy for retinitis pigmentosa

Teijin returns somavaratan rights to Versartis

European Commission extends Orkambi marketing authorization to children aged 6-11 years

Akcea Therapeutics starts phase IIb study of AKCEA-APOCIII-LRx

Axovant corrects data from pilot phase II study of nelotanserin

Advanced Proteome Therapeutics and Heidelberg Pharma advance collaboration

JTZ-951, a HIF-PH inhibitor, shows positive results for treating renal anemia

Japanese submission seeks approval of blinatumomab for relapsed or refractory B-cell precursor ALL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...